Download PDF
Dtsch Med Wochenschr 2000; 125(37): 1090-1094
DOI: 10.1055/s-2000-7358
Übersichten
© Georg Thieme Verlag Stuttgart · New York

Östrogenersatztherapie und Koronare Herzerkrankung

W. Lengfelder
  • Klinik für Kardiologie und Internistische Intensivmedizin (Chefarzt: Priv. Doz. Dr. W. Lengfelder) des Klinikums Minden
Further Information

Publication History

Publication Date:
31 December 2000 (online)

Also available at
    Permissions and Reprints

Über die Indikation zur Hormonersatztherapie in der Menopause bei der koronaren Herzerkrankung, deren positive Wirkung und auch deren potenzielle Nebenwirkungen herrscht häufig eine große Unsicherheit. Das kann dazu führen, dass Patientinnen einerseits günstige Effekte durch zu enge Indikationsstellung vorenthalten werden. Andererseits ist bei zu weiter Indikationsstellung oder Verordnung eines »falschen Hormonpräparates« mit Nebenwirkungen zu rechnen, die in keinem adäquaten Verhältnis zu den günstigen Wirkungen stehen. In dieser Arbeit soll eine Übersicht über die Wirksamkeit und Sicherheit der Hormonersatztherapie bei koronarer Herzkrankheit anhand des derzeitigen Standes der Literatur gegeben werden.

Literatur

  • 1 Andersson B, Mattsson L, Hahn L, Märin P, Lapidus L, Hohn G, Bengtsson B, Björntorp B. Estrogen replacement therapy decreases hyperandrogenecity and improves glucose homeostasis and plasma lipids in postmenopausal women with noninsulin dependent diabetes mellitus.  J Clin Endocrinol Metabol. 1997;  82 638-643
    Search in Google Scholar
  • 2 Bounameaux H, de Moerloose P, Campanne A. Contraception orale et substitution hormonale de la menopause.  Schweiz Med Wschr. 1996;  126 1756-1763
    Search in Google Scholar
  • 3 Collaborative study of cardiovascular disease and steroid hormone contraception.  Contraception. 1998;  57 315-324
    Search in Google Scholar
  • 4 Col N F, Eckmann M H, Karas R H, Paucker S G, Goldberg R J, Ross E M, Orr R K, Wong J B. Patient-specific decisions about hormone replacement therapy in postmenopausal womens.  J Am Med Ass. 1997;  277 1140-1147
    Search in Google Scholar
  • 5 Colditz G A, Willett W C, Stampfer M J. et al . Menopause and the risk of coronary heart disease in women.  N Engl J Med. 1987;  316 1105-1110
    Search in Google Scholar
  • 6 Colditz G A, Hankinson S E, Hunter D J. et al . The use of estrogens and progestins and the risk of breast cancer in postmenopausal women.  N Engl J Med. 1995;  332 1589-1593
    Search in Google Scholar
  • 7 Daly E, Vessey M P, Hawkins M M. et al . Risk of venous thromboembolism in users of hormone replacement therapy.  Lancet. 1996;  348 977-980
    Search in Google Scholar
  • 8 Dunn N, Thorogood M, Faragher B. et al . Oral contraceptives and myocardial infarction: results of the MICA case-control study.  Brit Med J. 1999;  318 1579-1584
    Search in Google Scholar
  • 9 Ettinger P, Friedman G D, Bush R, Quesenburg jr C P. Reduced mortality associated with long-term postmenopausal estrogen therapy.  Obstet Gynecol. 1996;  87 1-7
    Search in Google Scholar
  • 10 Folsorn A R, Mink P J, Selleres T A, Hong C P, Zheng W, Potter J D. Hormonal replacement therapy and morbidity and mortality in a prospective study of postmenopausal women.  Am J Public Health. 1995;  85 1128-1132
    Search in Google Scholar
  • 11 Gorsky R D, Koplan J P. et al . Relative risks and benefits of longterm estrogen replacement therapy.  Obstet Gynecol. 1994;  83 161-166
    Search in Google Scholar
  • 12 Grady D, Rubin S M, Petitti D, Fox C S, Black D, Ettinger B, Ernster V, Cummings S R. Hormone replacement therapy to prevent disease and prolong life in postmenopausal women.  Ann Int Med. 1992;  117 1038-1041
    Search in Google Scholar
  • 13 Grodstein F, Stampfer M J, Colditz G A. Postmenopausal hormone therapy and mortality.  N Engl J Med. 1997;  336 1769-1775
    Search in Google Scholar
  • 14 Grodstein F, Stampfer M J, Manson J E, Colditz G A, Willet W C, Rosner B, Speizer F, Hennekens C H. Postmenopausal estrogen and progestin use and the risk of cardiovascular disaese.  N Engl J Med. 1996;  335 453-461
    Search in Google Scholar
  • 15 Grodstein F, Stampfer M J, Goldhaber S Z, Manson J E, Coldis G A, Speizer F E, Willett W C, Hennekens C H. Prospective study of exogenous hormones and risk of pulmonary embolism in women.  Lancet. 1996;  248 1183-1186
    Search in Google Scholar
  • 16 Hennekens C H. Hormone replacement therapy: Current perspectives and future directions.  Eur Heart J. 1997;  19 1362-1363
    Search in Google Scholar
  • 17 Hertfelder H J, Hanfland P. Blutgerinnungsveränderungen unter Ovulationshemmung, in der Schwangerschaft und in der Postmenopause.  Herz/Kreislauf. 1999;  31 109-112
    Search in Google Scholar
  • 18 Hulley S, Grady D, Bush T, Furberg C, Herrington D, Vittinghoff E. for the Heart and Estrogen/Progestin Replacement study (HERS) research group . Rado○ized ▾rial of e▴▾roge plu▴ proge▴▾i for ▴ecodar▮ preve▾io of coroar▮ hear▾ di▴ea▴e i po▴▾○eopau▴al wo○e.  J Am Med Ass. 1998;  280 605-623
    Search in Google Scholar
  • 19 Jick H, Derby L E, Myers M W, Vasilaikis C, Newton K M. Risk of hosptital admission for idiopathic venous thromboembolism among users of postmenopausal estrogens.  Lancet. 1996;  348 981-983
    Search in Google Scholar
  • 20 Jordan V C. Designer-Östrogene: Neuartige Prävention gegen Brustkrebs und Osteoporose.  Spektrum der Wissenschaft. 1999;  ✗ 66-73
    Search in Google Scholar
  • 21 Koh K K, Mincemoyer R, Bui B N, Csako G, Pucino F, Guetta V, Waclawiw M, Cannon R O. Effects of hormone replacement therapy on fibrinolysis in postmenopausal women.  N Engl J Med. 1997;  336 683-690
    Search in Google Scholar
  • 22 Kommission Hormontoxikologie der Deutschen Gesellschaft für Endokrinologie . Östrogen/Gestagen-Substitution während und nach den Wechseljahren.  Endokrinologie. 1996;  20 122-125
    Search in Google Scholar
  • 23 Mant J, Painter R, Vessey M. Risk of myocardial infarction, angina and stroke in users of oral contraceptives: updated analysis of a cohort study.  Br J Obstet Gynaekcol. 1998;  105 890-896
    Search in Google Scholar
  • 24 Mendelsohn M E, Karas R H. Mechanism of Disease: The protective effects of Estrogen on the cardiovascular system.  N Engl J Med. 1999;  340 1801
    Search in Google Scholar
  • 25 O`Brian J E, Peterson E D, Keeler G P. Relation between estrogen replacement therapy and restenosis after percutaneous coronary interventions.  J Am Coll Cardiol. 1996;  28 1111-1118
    Search in Google Scholar
  • 26 Oger E, Scarabin P Y. Assessment of the risk for venous thromboembolism among users of the hormone replacement therapy.  Drugs Aging. 1999;  14 55-61
    Search in Google Scholar
  • 27 Peterson L. Estrogen replacement therapy and coronary heart disease.  Curr Opin Cardiol. 1998;  13 223-231
    Search in Google Scholar
  • 28 Psaty B M, Heckbert S R, Atkins D. et al . The risk of myocardial infarction associated with the combined use of estrogen and progestin in postmenopausal women.  Arch Int Med. 1994;  154 1333-1339
    Search in Google Scholar
  • 29 Rich-Edwards J W, Manson J, Hennekens C H, Buring J E. The primary prevention of coronary heart disease in women.  N Engl J Med. 1995;  332 1758-1766
    Search in Google Scholar
  • 30 Rich-Edwards J W, Hennekens C H. Postmenopuasal hormones and coronary heart disease.  Curr Opin Cardiol. 1996;  12 440-446
    Search in Google Scholar
  • 31 Ringe J D, Nickelsen T h. Raloxifen.  Arzneimitteltherapie. 1999;  17 113-120
    Search in Google Scholar
  • 32 Schunkert H, Danser A H-J, Hense H, Derks F H-M, Kürzinger S, Rigger G A-J. Effects of estrogen replacement therapy of the renin-angiotensin system in postmenopausal women.  Circulation. 1997;  95 39-45
    Search in Google Scholar
  • 33 Sherif K. Benefits and risks of oral contraceptives.  Am J Obstet Gynecol. 1999;  180 343-348
    Search in Google Scholar
  • 34 Skouby S O. Oral contraceptives and venous thrombosis: End of the debate?.  Eur J Contracept Reprod Health Care. 1998;  3 59-64
    Search in Google Scholar
  • 35 Stadel B V. Oral contraceptives and cardiovascular disease.  N Engl J Med. 1993;  328 1069-1075
    Search in Google Scholar
  • 36 Stampfer M J, Willett W C, Colditz G A, Rosner B, Speizer F E, Hennekens C H. A prospective study of the meonopausal estrogen therapy and coronary heart disease.  N Engl J Med. 1985;  313 1044-1049
    Search in Google Scholar
  • 37 Stampfer M J, Colditz G A, Willett W C. et al . Postmenopausal estrogen therapy and cardiovascular disease.  N Engl J Med. 1991;  325 756-762
    Search in Google Scholar
  • 38 Stampfer M J, Colditz G A. Estrogen replacement therapy and coronary heart disase: A quantitative assessment of the epidemiologic evidence.  Prev Med. 1991;  20 47-63
    Search in Google Scholar
  • 39 Sullivan J M, El-Zeky F, Vander Zwang R, Ramanathan K B. Effect on survival of estrogen replacement therapy after coronary artery bypass grafting.  Am J Cardiol. 1997;  79 847-850
    Search in Google Scholar
  • 40 Sourander L, Rajala T, Makinen I. et al . Cardiovascular and cancer morbidity and mortality and sudden cardiac death in postmenopausal women on estrogen replacement therapy.  Lancet. 1998;  352 1965-1969
    Search in Google Scholar
  • 41 Todd J, Lawrenson R, Farmer R D, Williams T J, Leyden G M. Venous thromboembolic disease and combined oral contraceptives: A reanalysis of the MedPlus database.  Hum Reprod. 1999;  14 1500-1005
    Search in Google Scholar
  • 42 Weiss G. Risk of venous thromboembolism with third generation oral contraceptives. A review.  Am J Obstet Gynecol. 1999;  180 295-301
    Search in Google Scholar
  • 43 The writing group for the PEPI trial . Effects of estrogen or Estrogen/Progestin Regimens on heart disease: Risk factors in postmenopausal women. The postmenopausal Estrogen/Progestin interventions(PEPI) trial.  J Am Med Ass. 1995;  273 199-208
    Search in Google Scholar
  • 44 Windler E. Prävention kardiovaskulärer Erkrankungen durch Hormonsubstitution in der Postmenopause.  Zentralbl Gynäkol. 1996;  118 188-197
    Search in Google Scholar

Korrespondenz

Privatdozent Dr. W. Lengfelder

Klinik für Kardiologie und Internistische Intensivmedizin Klinikum Minden

Postfach

32390 Minden

Phone: 0571/8013012,

Fax: 0571/8013015